Role of MRI Diffusion in Differentiation Between Benign and Malignant Bony Lesions

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03463291

Enrollment

Registered

2018-03-13

Start date

2018-05-31

Completion date

2020-07-31

Last updated

2018-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Efficacy of MRI Diffusion in Differentiation Between Benign and Malignant Bony Lesions

Brief summary

Bone tumors are categorized according to their tissue of origin into cartilagenous, osteogenic, fibrogenic, fibrohistiocytic, haematopoietic, vascular, and lipogenic tumors. Magnetic resonance imaging (MRI) is now indispensable for the preoperative workup and therapeutic follow-up of patients with musculoskeletal tumors. The application of DW-MRI in bone marrow is today an established examination technique that provides a unique contrast and that can help in the detection of bone-marrow pathologies and the differentiation of benign and malignant bone-marrow lesions. Diffusion MRI provides quantitative and qualitative assessments of tissue cellularity and cell-membrane integrity. It is widely used for tumour detection, characterisation, and monitoring during treatment. Diffusion MRI supplies functional information that complements the structural evaluation. In combination with standard structural MRI parameters, the ADC value improves tumour characterization. Diffusion MRI can also be used to monitor tumours during chemotherapy. Tumour necrosis results in loss of cell membrane integrity and in expansion of the extracellular compartment, leading to greater water-molecule diffusion with an increase in the ADC value.

Interventions

DEVICEMRI

* T1 weighted image. * Fast spin-echoT2 weighted image. * Short inversion recovery (STIR). * T1-fat suppressed images. * Diffusion weighted sequences with different b values 0-1000 s/mm2 with qualitative assessments by the different b values as well as quantitative assessment by measurement of the ADC values.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* All patients with bony lesions will be included in the study.

Exclusion criteria

* Patient with cardiac pacemaker. * Patients with metallic prosthesis in the region of examination. * Patients with claustrophobia. * Patient with recent history of surgical or imagining guided biopsy from the bony lesion.

Design outcomes

Primary

Measure	Time frame
The ADC value of MRI diffusion in benign and malignant bony lesions ( considering ADC value <1.2 ..malignant while ADC>1.2 ..benign)	1 day

Contacts

Primary ContactAmr M Attia

hexen_22us@yahoo.com+201270092886

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026